score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Nonsense	p.E59*	0.2889	180.0	0.0	0.0		Investigate Actionability	Afatinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.	Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0				EGFR p.E59* (Nonsense)	1.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Guideline		Guideline	Somatic Variant	KIT	Missense	p.N822Y	0.3786	4701.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0.0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf	0				KIT p.N822Y (Missense)	0.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.K504Q	0.0669	344.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0				PDGFRA p.K504Q (Missense)	0.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.F156L	0.1894	417.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0.0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18	0				KRAS p.F156L (Missense)	1.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R1875*	0.3987	158.0	1.6e-05	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007													0				ATM p.R1875* (Nonsense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S162F	0.2059	34.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143													0				GATA3 p.S162F (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.0497	161.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475													0				ERBB2 p.S310F (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat110		
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.F621I	0.2589	197.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14						0				FLT3 p.F621I (Missense)	1.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S389L	0.2233	206.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14						0				FLT3 p.S389L (Missense)	1.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.D305N	0.3077	104.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0				ALK p.D305N (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E71K	0.3866	194.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.E71K (Missense)	1.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.E127K	0.6875	32.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230													0				AKT1 p.E127K (Missense)	0.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176G	0.9167	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				TP53 p.C176G (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P310S	0.3017	116.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf						0				ABL1 p.P310S (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.R1013W	0.3103	58.0	8e-06	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf						0				ABL1 p.R1013W (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S305F	0.88	50.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				SETBP1 p.S305F (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat110		
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Splice Site		0.1562	64.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0				EGFR  (Splice Site)	1.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E914K	0.3929	252.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA1 p.E914K (Missense)	1.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.P315L	0.2311	238.0	4.1e-05	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				BARD1 p.P315L (Missense)	0.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.P368L	0.1966	524.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				BRIP1 p.P368L (Missense)	1.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.Q203H	0.3889	72.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0				RAD54L p.Q203H (Missense)	0.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Splice Site		0.0535	411.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0				PDGFRA  (Splice Site)	0.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P413L	0.28800000000000003	125.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf													0				TET2 p.P413L (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L901F	0.6102	254.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA2 p.L901F (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.L778F	0.3073	397.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.L778F (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.L778P	0.3077	390.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.L778P (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.P850S	0.3742	310.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MLH3 p.P850S (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Splice Site		0.2667	90.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14						0				FLT3  (Splice Site)	0.0	MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1885S	0.5536	112.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0				ARID1A p.P1885S (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R966W	0.28300000000000003	53.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098													0				SMARCA4 p.R966W (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.S371L	0.2162	37.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405						0				BCR p.S371L (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.A336T	0.1882	85.0	0.0	0.0																Investigate Actionability	0.0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				ETV6 p.A336T (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Investigate Actionability			Clinical evidence	Copy Number	PAK1	Deletion				0.0	0.0																Investigate Actionability	0.0	PAK1 amplification showed reduced recurrence-free survival and decreased benefit from Tamoxifen in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506	0				PAK1 Deletion		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S2035F	0.027000000000000003	296.0	0.0	0.0																					0				MTOR p.S2035F (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R1009W	0.0597	67.0	3.3e-05	0.0																					0				MTOR p.R1009W (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.G487D	0.2593	27.0	8e-06	0.0																					0				SLC45A3 p.G487D (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	RAF1	Missense	p.L136F	0.1837	441.0	0.0	0.0																					0				RAF1 p.L136F (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.P129S	0.2712	59.0	0.0	0.0																					0				PDGFRB p.P129S (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	ROS1	Splice Site	p.T2045T	0.3875	80.0	8.2e-05	0.0																					0				ROS1 p.T2045T (Splice Site)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1929S	0.3659	41.0	0.0	0.0																					0				ROS1 p.P1929S (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1710S	0.0484	124.0	8e-06	0.0																					0				ROS1 p.P1710S (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1244K	0.4416	77.0	0.0	0.0																					0				ROS1 p.E1244K (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G242E	0.3057	157.0	8e-06	0.0																					0				ROS1 p.G242E (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.M365I	0.1859	156.0	0.0	0.0																					0				RUNX1T1 p.M365I (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E339K	0.2273	242.0	0.0	0.0																					0				RUNX1T1 p.E339K (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E261K	0.225	120.0	0.0	0.0																					0				RUNX1T1 p.E261K (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D220N	0.4512	82.0	0.0	0.0																					0				RUNX1T1 p.D220N (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.V477A	0.1928	83.0	0.0	0.0																					0				ESRP1 p.V477A (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R29*	1.0	23.0	0.0	0.0																					0				CDKN2A p.R29* (Nonsense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S790F	0.1366	161.0	0.0	0.0																					0				FGFR2 p.S790F (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	FGFR2	Splice Site	p.E769K	0.1675	209.0	1.6e-05	0.0																					0				FGFR2 p.E769K (Splice Site)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.M735I	0.2143	28.0	0.0	0.0																					0				FGFR2 p.M735I (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.M585I	0.2043	186.0	0.0	0.0																					0				FGFR2 p.M585I (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.T137I	0.305	141.0	0.0	0.0																					0				FGFR2 p.T137I (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	FLI1	Splice Site		0.4396	182.0	0.0	0.0																					0				FLI1  (Splice Site)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	FLI1	Splice Site	p.G4D	0.4396	182.0	0.0	0.0																					0				FLI1 p.G4D (Splice Site)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	FLI1	Missense	p.R20Q	0.4493	207.0	8e-06	0.0																					0				FLI1 p.R20Q (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.P725L	0.4595	37.0	0.0	0.0																					0				NTRK3 p.P725L (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D467N	0.5781	64.0	0.0	0.0																					0				NTRK3 p.D467N (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.K466N	0.5873	63.0	0.0	0.0																					0				NTRK3 p.K466N (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q282*	0.7317	41.0	0.0	0.0																					0				NF1 p.Q282* (Nonsense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.E207K	0.2526	95.0	0.0	0.0																					0				IL12RB1 p.E207K (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.P295S	0.2075	294.0	0.00010700000000000001	0.0																					0				CCNE1 p.P295S (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	ERG	Missense	p.S222F	0.1552	58.0	0.0	0.0																					0				ERG p.S222F (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.A483T	0.0431	116.0	0.0	0.0																					0				LIMK2 p.A483T (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S531F	0.1867	75.0	0.0	0.0																					0				LIMK2 p.S531F (Missense)		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	MEL-IPI_Pat110-Normal-SM-4MGPO
Biologically Relevant				Copy Number	KIT	Amplification				0.0	0.0																					0				KIT Amplification		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	
Biologically Relevant				Copy Number	PDGFRA	Amplification				0.0	0.0																					0				PDGFRA Amplification		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	
Biologically Relevant				Copy Number	FIP1L1	Amplification				0.0	0.0																					0				FIP1L1 Amplification		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	
Biologically Relevant				Copy Number	ESRP1	Amplification				0.0	0.0																					0				ESRP1 Amplification		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	
Biologically Relevant				Copy Number	ALK	Amplification				0.0	0.0																					0				ALK Amplification		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	
Biologically Relevant				Copy Number	NF1	Deletion				0.0	0.0																					0				NF1 Deletion		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	
Biologically Relevant				Copy Number	POLE	Deletion				0.0	0.0																					0				POLE Deletion		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	
Biologically Relevant				Copy Number	SETBP1	Deletion				0.0	0.0																					0				SETBP1 Deletion		MEL-IPI_Pat110	MEL-IPI_Pat110-Tumor-SM-4CU6X	
Biologically Relevant				Microsatellite Stability	Supporting variants		DOCK3 p.W1922* (Nonsense), ESRP1 Amplification, POLE Deletion, PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: DOCK3 p.W1922* (Nonsense), ESRP1 Amplification, POLE Deletion, PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat110		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.828																									0				COSMIC Signature (version 2) 7 (83%)		MEL-IPI_Pat110		
